

DAFTAR PUSTAKA

- Abdel Halim, I.I., El Ashri, M., dan El Sadda, W., 2011. Weekly paclitaxel versus standard 3-week schedule in patients with metastatic breast cancer. *Journal of Clinical Oncology*, **29**: 627–627.
- Aldredge, B.K., Jacobson, P.A., Corelli, R.L., Ernst, M.E., dan Guglielmo, B.J., 2013. *Koda-Kimble & Young's Applied Therapeutics, Tenth Edition + Foye's Principles of Medicinal Chemistry, Seventh Edition*. Lippincott Williams & Wilkins.
- Amandito, R., Viryawan, C., Santoso, F., Gautami, W., dan Panigoro, S.S., 2013. The Characteristics of Breast Cancer Patients in “Dharmais” Hospital National Cancer Center Jakarta Based on Occupational and Environmental Status 7 .
- Angela, D., Djohan Ardiansyah, Desak Gede Agung Suprabawati, 2022. Hubungan intensitas nyeri dengan kualitas hidup pasien kanker payudara yang menjalani kemoterapi di PPLK RSUD Dr. Soetomo. *Intisari Sains Medis* 13(1): 109-116. DOI: 10.15562/ism.v13i1.1236.
- Azam, F., Latif, M.F., Farooq, A., Tirmazy, S.H., AlShahrani, S., Bashir, S., dkk., 2019. Performance Status Assessment by Using ECOG (Eastern Cooperative Oncology Group) Score for Cancer Patients by Oncology Healthcare Professionals. *Case Reports in Oncology*, **12**: 728–736.
- Breast Cancer Agency, 2023. Breast. Available <http://www.bccancer.bc.ca/health-professionals/clinical-resources/chemotherapy-protocols/breast> (diakses tanggal 16/1/2023).

Breast Cancer Facts & Figures. American Cancer Society. (n.d.). Retrieved August 21, 2022, from <https://www.cancer.org/research/cancer-facts-statistics/breast-cancer-facts-figures.html>.

Brandt, J., Garne, J.P., Tengrup, I., dan Manjer, J., 2015. Age at diagnosis in relation to survival following breast cancer: a cohort study. *World Journal of Surgical Oncology*, **13**: 33.

Bissery, M.C., 1995. Preclinical pharmacology of docetaxel. *European Journal of Cancer (Oxford, England: 1990)*, **31A Suppl 4**: S1-6.

Bissery, M.C., Nohynek, G., Sanderink, G.J., dan Lavelle, F., 1995. Docetaxel (Taxotere): a review of preclinical and clinical experience. Part I: Preclinical experience. *Anti-Cancer Drugs*, **6**: 339–355, 363–368.

Camps, C., Massuti, B., Jiménez, A., Maestu, I., Gómez, R.G., Isla, D., dkk., 2006. Randomized phase III study of 3-weekly versus weekly docetaxel in pretreated advanced non-small-cell lung cancer: a Spanish Lung Cancer Group trial. *Annals of Oncology*, **17**: 467–472.

CDC, 2022. What Are the Risk Factors for Breast Cancer?. Centers for Disease Control and Prevention https://www.cdc.gov/cancer/breast/basic_info/risk_factors.htm (diakses tanggal 28/6/2023).

Chen, H., Zhou, M., Tian, W., Meng, K., dan He, H., 2016. Effect of Age on Breast Cancer Patient Prognoses: A Population-Based Study Using the SEER 18 Database. *PLoS ONE*, **11**: e0165409.

Cheng, S., Qureshi, M., Pullenayegum, E., Haynes, A., dan Chan, K.K., 2017.

Do patients with reduced or excellent performance status derive the same clinical benefit from novel systemic cancer therapies? A systematic review and meta-analysis. *ESMO Open*, **2**: e000225.

Conill, C., Verger, E., dan Salamero, M., 1990. Performance status assessment in cancer patients. *Cancer*, **65**: 1864–1866.

Curigliano, G., Criscitiello, C., Esposito, A., Fumagalli, L., Gelao, L., Locatelli, M., dkk., 2013. Best management of locally advanced inoperable breast cancer. *EJC Supplements*, **11**: 289–290.

Dahlan, M. Sopiudin, 2016. Analisis Multivariat Regresi Logistik Disertai Praktik dengan Program SPSS dan Stata. Jakarta: PT. Epidemiologi Indonesia.

Dinas Komunikasi dan Informatika Provinsi Jawa Timur, 2020. Serviks dan Payudara, Dominasi Kanker di Jawa Timur URL: <https://kominfo.jatimprov.go.id/berita/serviks-dan-payudara-dominasi-kanker-di-jawa-timur-> (diakses tanggal 16/1/2023).

DiPiro, J.T., DiPiro, C.V., Ellingrod, V., dan Schwinghammer, T.L., 2021. *Pharmacotherapy Handbook, Eleventh Edition*. McGraw-Hill Education.

Eijk, M., Vermunt, M.A.C., van Werkhoven, E., Wilthagen, E.A., Huitema, A.D.R., dan Beijnen, J.H., 2022. The influence of docetaxel schedule on treatment tolerability and efficacy in patients with metastatic breast cancer: a

systematic review and meta-analysis of randomized controlled trials. *BMC Cancer*, **22**: 104.

Elmika, E., Mateus Sakundarno Adi, 2020. Gambaran Umur, dan Jenis Kelamin Pasien Kanker Payudara di RS Ibnu Sina Kota Makassar. *Jurnal Penelitian Kesehatan Suara Forikes*.

Fan, Y., Khan, N.H., Farhan Ali Khan, M., Ahammad, M.D.F., Zulfiqar, T., Virk, R., dkk., 2022. Association of Hypertension and Breast Cancer: Antihypertensive Drugs as an Effective Adjunctive in Breast Cancer Therapy. *Cancer Management and Research*, 14: 1323–1329.

Farha, N.G. dan Kasi, A., 2022. *Docetaxel*, StatPearls [Internet]. StatPearls Publishing.

Grohé, C., Wehler, T., Henschke, S., Dittrich, I., Hammerschmidt, S., Aulmann, C., dkk., 2022. Effect of performance status (ECOG PS) on treatment outcome with second-line (2L) nintedanib (NIN) + docetaxel (DOC) for patients (pts) with lung adenocarcinoma after first-line (1L) immune checkpoint inhibitor (ICI) combination therapy. *Journal of Clinical Oncology*, **40**: 9092–9092.

Grose, D., Devereux, G., Brown, L., Jones, R., Sharma, D., Selby, C., dkk., 2011. Variation in comorbidity and clinical management in patients newly diagnosed with lung cancer in four Scottish centers. *Journal of Thoracic Oncology: Official Publication of the International Association for the Study of Lung Cancer*, **6**: 500–509.

- Han, H., Guo, W., Shi, W., Yu, Y., Zhang, Y., Ye, X., dkk., 2017. Hypertension and breast cancer risk: a systematic review and meta-analysis. *Scientific Reports*, 7: 44877.
- Harvey, V., Mouridsen, H., Semiglazov, V., Jakobsen, E., Voznyi, E., Robinson, B.A., dkk., 2006. Phase III Trial Comparing Three Doses of Docetaxel for Second-Line Treatment of Advanced Breast Cancer. *Journal of Clinical Oncology*, **24**: 4963–4970.
- Hennequin, C., Giocanti, N., dan Favaudon, V., 1995. S-phase specificity of cell killing by docetaxel (Taxotere) in synchronised HeLa cells. *British Journal of Cancer*, **71**: 1194–1198.
- Hosmer, David W. and Stanley Lemeshow, 2000. *Applied Logistic Regression* Second Edition. New York: John Wiley & Sons, Inc.
- Hutajulu, S.H., Prabandari, Y.S., Bintoro, B.S., Wiranata, J.A., Widiastuti, M., Suryani, N.D., dkk., 2022. Delays in the presentation and diagnosis of women with breast cancer in Yogyakarta, Indonesia: A retrospective observational study. *PLOS ONE*, 17: e0262468.
- Kalli, S., Semine, A., Cohen, S., Naber, S.P., Makim, S.S., dan Bahl, M., 2018. American Joint Committee on Cancer’s Staging System for Breast Cancer, Eighth Edition: What the Radiologist Needs to Know. *RadioGraphics*, **38**: 1921–1933.
- Käsmann, L., Taugner, J., Eze, C., Roengvoraphoj, O., Dantes, M., Gennen, K., dkk., 2019. Performance Status and Its Changes Predict Outcome for

Patients With Inoperable Stage III NSCLC Undergoing Multimodal Treatment. *Anticancer Research*, 39: 5077–5081.

Kelly, C.M. dan Shahrokni, A., 2016. Moving beyond Karnofsky and ECOG Performance Status Assessments with New Technologies. *Journal of Oncology*, **2016**: 6186543.

Kemkes, 2013. Pedoman Teknis Pengendalian Kanker Payudara dan Kanker Leher Rahim. Direktorat PP & PL Direktorat Pengendalian Penyakit Tidak Menular.

Kemkes, 2019. Penyakit Kanker di Indonesia Berada Pada Urutan 8 di Asia Tenggara dan Urutan 23 di Asia. URL:<http://p2p.kemkes.go.id/penyakit-kanker-di-indonesia-berada-pada-urutan-8-di-asia-tenggara-dan-urutan-23-di-asia/>.

Kemkes, 2022. Kanker Payudara Paling Banyak di Indonesia, Kemenkes Targetkan Pemerataan Layanan Kesehatan. URL: <https://www.kemkes.go.id/article/view/22020400002/kanker-payudara-paling-banyak-di-indonesia-kemenkes-targetkan-pemerataan-layanan-kesehatan.html>.

Kenmotsu, H. dan Tanigawara, Y., 2015. Pharmacokinetics, dynamics and toxicity of docetaxel: Why the Japanese dose differs from the Western dose. *Cancer Science*, **106**: 497–504.

Khanna, A., 2017. Late Presentation of Lung Cancer in the Developing World and the Unique Challenges We Face in Managing this Disease: Assessment

of Quality of Life (QOL), Performance Status (PS) and Their Correlation with Staging at the Time of Diagnosis, dalam: B80-L. GENERAL THORACIC ONCOLOGY, American Thoracic Society International Conference Abstracts. American Thoracic Society, hal. A7638–A7638.

Kida, K., Hess, K.R., Lim, B., Iwase, T., Chainitikun, S., Valero, V., dkk., 2020. Validation of Prognostic Stage and Anatomic Stage in the American Joint Committee on Cancer 8th Edition for Inflammatory Breast Cancer. *Cancers*, 12: 3105.

Koné, A.P. dan Scharf, D., 2021. Prevalence of multimorbidity in adults with cancer, and associated health service utilization in Ontario, Canada: a population-based retrospective cohort study. *BMC Cancer*, **21**: 406.

Koné Pefoyo, A.J., Bronskill, S.E., Gruneir, A., Calzavara, A., Thavorn, K., Petrosyan, Y., dkk., 2015. The increasing burden and complexity of multimorbidity. *BMC Public Health*, **15**: 415.

Köhne, C.H., Cunningham, D., Di Costanzo, F., Glimelius, B., Blijham, G., Aranda, E., dkk., 2002. Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients. *Annals of Oncology: Official Journal of the European Society for Medical Oncology*, **13**: 308–317.

Madeddu, C., Gramignano, G., Astara, G., Demontis, R., Sanna, E., Atzeni, V., dkk., 2018. Pathogenesis and Treatment Options of Cancer Related Anemia: Perspective for a Targeted Mechanism-Based Approach. *Frontiers in Physiology*, 9: 1294.

- Manoharan, N., Nair, O., Shukla, N.K., dan Rath, G.K., 2017. Descriptive Epidemiology of Female Breast Cancer in Delhi, India. *Asian Pacific journal of cancer prevention: APJCP*, **18**: 1015–1018.
- Martín, M., de la Torre-Montero, J.C., López-Tarruella, S., Pinilla, K., Casado, A., Fernandez, S., dkk., 2018. Persistent major alopecia following adjuvant docetaxel for breast cancer: incidence, characteristics, and prevention with scalp cooling. *Breast Cancer Research and Treatment*, 171: 627–634.
- Massacesi, C., Marcucci, F., Rocchi, M.B.L., Mazzanti, P., Pilone, A., dan Bonsignori, M., 2004. Factors Predicting Docetaxel-Related Toxicity: Experience at a Single Institution. *Journal of Chemotherapy*, **16**: 85–93.
- Moningi, S., Walker, A.J., Hsu, C.C., Reese, J.B., Wang, J.-Y., Fan, K.Y., dkk., 2015. Correlation of clinical stage and performance status with quality of life in patients seen in a pancreas multidisciplinary clinic. *Journal of Oncology Practice*, 11: e216-221.
- Menkes, R.I., 2018. Pedoman Nasional Pelayanan Kedokteran Tata Laksana Kanker Payudara.
- Nathania, R., Fahman, J., Saroso, O.J.D.A., Raffaello, W.M., Putri, H., Wijovi, F., dkk., 2019. Association Between Performance Status and Quality of Life in Breast Cancer Patients: A Preliminary Study. *Annals of Oncology*, 30: vi146.

Nayak, M.G., George, A., Vidyasagar, M., Mathew, S., Nayak, S., Nayak, B.S., dkk., 2017. Quality of Life among Cancer Patients. *Indian Journal of Palliative Care*, 23: 445–450.

National Comprehensive Cancer Network (NCCN), 2021. n.d. NCCN. URL: <https://www.nccn.org/guidelines/guidelines-detail> (diakses tanggal 22/12/2021).

Ng, H.S., Vitry, A., Koczwara, B., Roder, D., dan McBride, M.L., 2019. Patterns of comorbidities in women with breast cancer: a Canadian population-based study. *Cancer causes & control: CCC*, **30**: 931–941.

Nuzzo, F., Morabito, A., De Maio, E., Di Rella, F., Gravina, A., Labonia, V., dkk., 2008. Weekly docetaxel versus CMF as adjuvant chemotherapy for elderly breast cancer patients: safety data from the multicentre phase 3 randomised ELDA trial. *Critical Reviews in Oncology/Hematology*, 66: 171–180.

Nuzzo, F., Morabito, A., Gravina, A., Di Rella, F., Landi, G., Pacilio, C., dkk., 2011. Effects on quality of life of weekly docetaxel-based chemotherapy in patients with locally advanced or metastatic breast cancer: results of a single-centre randomized phase 3 trial. *BMC Cancer*, **11**: 75.

Palmeri, L., Vaglica, M., dan Palmeri, S., 2008. Weekly docetaxel in the treatment of metastatic breast cancer. *Therapeutics and Clinical Risk Management*, **4**: 1047–1059.

Prieto-Callejero, B., Rivera, F., Fagundo-Rivera, J., Romero, A., Romero-Martín, M., Gómez-Salgado, J., dkk., 2020. Relationship between chemotherapy-induced adverse reactions and health-related quality of life in patients with breast cancer. *Medicine*, 99: e21695.

Prigerson, H.G., Bao, Y., Shah, M.A., Paulk, M.E., LeBlanc, T.W., Schneider, B.J., dkk., 2015. Chemotherapy Use, Performance Status, and Quality of Life at the End of Life. *JAMA oncology*, 1: 778–784.

Rivera, E., Mejia, J.A., Arun, B.K., Adinin, R.B., Walters, R.S., Brewster, A., dkk., 2008. Phase 3 study comparing the use of docetaxel on an every-3-week versus weekly schedule in the treatment of metastatic breast cancer. *Cancer*, 112: 1455–1461.

Schiller, J.H., Harrington, D., Belani, C.P., Langer, C., Sandler, A., Krook, J., dkk., 2002. Comparison of Four Chemotherapy Regimens for Advanced Non-Small-Cell Lung Cancer. *New England Journal of Medicine*, 346: 92–98.

Sharma, N., Narayan, S., Sharma, R., Kapoor, A., Kumar, N., dan Nirban, R., 2015. Association of comorbidities with breast cancer: An observational study. *Tropical Journal of Medical Research*, 19.

Sihombing, M. dan Sapardin, A.N., 2014. Faktor Risiko Tumor Payudara Pada Perempuan Umur 25-65 Tahun Di Lima Kelurahan Kecamatan Bogor Tengah. *Jurnal Kesehatan Reproduksi*, 5: 175–184.

- Sinaga, E.S., Ahmad, R.A., Shivalli, S., dan Hutajulu, S.H., 2018. Age at diagnosis predicted survival outcome of female patients with breast cancer at a tertiary hospital in Yogyakarta, Indonesia. *The Pan African Medical Journal*, 31: 163.
- Sinulingga, D.I., 2014. 'Korelasi Short Form-36 dengan Skala Eastern Cooperative Oncology Group dalam Menilai Kualitas Hidup pada Pasien Limfoma Non Hodgkin yang Mendapat Kemoterapi Regimen Cyclophosphamide, Doxorubicin, Vincristine, dan Prednisone', Thesis,. Universitas Sumatera Utara.
- Schrijvers, D., 2011. Management of anemia in cancer patients: transfusions. *The Oncologist*, 16 Suppl 3: 12–18.
- Shah, R., Rosso, K., dan Nathanson, S.D., 2014. Pathogenesis, prevention, diagnosis and treatment of breast cancer. *World Journal of Clinical Oncology*, 5: 283–298.
- Sharma, N., Narayan, S., Sharma, R., Kapoor, A., Kumar, N., dan Nirban, R., 2015. Association of comorbidities with breast cancer: An observational study. *Tropical Journal of Medical Research*, 19.
- Sorbe, B., Graflund, M., Nygren, L., dan Horvath, G., 2013. A study of docetaxel weekly or every three weeks in combination with carboplatin as first line chemotherapy in epithelial ovarian cancer: Hematological and non-hematological toxicity profiles. *Oncology Letters*, 5: 1140–1148.

Stanley, K.E., 1980. Prognostic Factors for Survival in Patients With Inoperable Lung Cancer². *JNCI: Journal of the National Cancer Institute*, **65**: 25–32.

Van Cutsem, E., Peeters, M., Siena, S., Humblet, Y., Hendlisz, A., Neyns, B., et al., 2007. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. *Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology*, **25**: 1658–1664.

Taylor, A.E., Olver, I.N., Sivanthan, T., Chi, M., dan Purnell, C., 1999. Observer error in grading performance status in cancer patients. *Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer*, **7**: 332–335.

Taxotere, 2020 Bridgewater, NJ: Sanofi-Aventis US.LLC.; https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/020449s084lbl.pdf.

Utami, W., Widayati, K., dan Rahmawati, F., 2020. Hubungan Penggunaan Antihipertensi Terhadap Rekurensi pada Pasien Kanker Payudara non Metastasis. *Majalah Farmaseutik*, **16**: 131–140.

West, H. (Jack) dan Jin, J.O., 2015. Performance Status in Patients With Cancer. *JAMA Oncology*, **1**: 998.

WHO, 2016. Multimorbidity: Technical Series on Safer Primary Care. Geneva: World Health Organization; 2016. Licence: CC BY-NC-SA 3.0 IGO.

WHO, 2020. International Agency for Research on Cancer: Indonesia. World Health Organization.

Wulandari, F., Widayati, K., dan Rahmawati, F., 2019. Hubungan Penyakit Diabetes Melitus dan Penggunaan Antidiabetes terhadap Rekurensi pada Pasien Kanker Payudara. JURNAL MANAJEMEN DAN PELAYANAN FARMASI (Journal of Management and Pharmacy Practice), 9: 294–302.

Zhao, X.-B. dan Ren, G.-S., 2016. Diabetes mellitus and prognosis in women with breast cancer: A systematic review and meta-analysis. Medicine, 95: e5602.

Zhao, Y., Wang, Q., Zhao, X., Meng, H., dan Yu, J., 2018. Effect of antihypertensive drugs on breast cancer risk in female hypertensive patients: Evidence from observational studies. Clinical and Experimental Hypertension (New York, N.Y.: 1993), 40: 22–27.